Capital Research Global Investors Allogene Therapeutics, Inc. Transaction History

Capital Research Global Investors

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $71 Million - $133 Million	-5,404,294 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $126 - $165	-6 Reduced -0.0%	5,404,294 $139 Million
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $171 Million - $260 Million	-7,259,713 Reduced 57.33%	5,404,300 $141 Million
Q1 2021 May 14, 2021	BUY	$25.79 - $39.02 $610,578 - $923,798	23,675 Added 0.19%	12,664,013 $447 Million
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $564,013 - $970,933	22,346 Added 0.18%	12,640,338 $319 Million
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $19.7 Million - $27.4 Million	609,223 Added 5.07%	12,617,992 $476 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $55.8 Million - $164 Million	3,036,198 Added 33.84%	12,008,769 $514 Million
Q1 2020 May 15, 2020	BUY	$18.22 - $28.25 $44.3 Million - $68.6 Million	2,429,893 Added 37.14%	8,972,571 $174 Million
Q4 2019 Feb 18, 2020	BUY	$24.82 - $31.4 $31.5 Million - $39.8 Million	1,268,228 Added 24.04%	6,542,678 $170 Million
Q3 2019 Nov 14, 2019	BUY	$26.11 - $32.99 $626 - $791	24 Added 0.0%	5,274,450 $144 Million
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $49.2 Million - $59.8 Million	1,923,894 Added 57.42%	5,274,426 $142 Million
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $20.9 Million - $27.4 Million	843,344 Added 33.64%	3,350,532 $95.7 Million
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $56.4 Million - $83.5 Million	2,507,188 New	2,507,188 $62.6 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

Stay updated on Capital Research Global Investors with notifications on news.